Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial - Pujade-Lauraine, Éric; Selle, F.; Scambia, G.; Asselain, B.; Marmé, Frederik; Lindemann, K.; Colombo, N.; Mądry, R.; Glasspool, R.; Vergote, Ignace B.; Korach, J.; Lheureux, S.; et al. (Annals of oncology, 2023)
Online verfügbar: 4. Oktober 2023, Artikelversion: 10. Dezember 2023